HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use DILANTIN® safely and effectively. See full prescribing information for DILANTIN®.
INFATABS® DILANTIN® (phenytoin chewable tablets), for oral use
Initial U.S. Approval: 1953
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
DILANTIN INFATABS are indicated for the treatment of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
DILANTIN INFATABS are available as 50 mg phenytoin scored chewable tablets. (3)
WARNINGS AND PRECAUTIONS
The most common adverse reactions are nervous system reactions, including nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.